- The availability of generic simvastatin and atorvastatin has significantly reduced overall expenditure on statins in England.
- When costs are similar, potency appears to influence prescribing choice.
Why this matters
- Expenditure on statins has been a significant contributor to the increasing burden on the National Health Service budget.
- During the period 1998 to 2004, driven by branded simvastatin and atorvastatin, a 125% increase in the primary care expenditure on statins was recorded (from £170,388,500 to £738,114,800).
- The average strengths of prescribed generic simvastatin and atorvastatin were significantly higher than branded simvastatin (P<.005 and atorvastatin respectively.>
- After patent expiry of branded simvastatin in 2003, generic simvastatin achieved 66% of the statins market share by 2011.
- Similarly, after the patent expiry of branded atorvastatin in 2012, generic atorvastatin had 50% of the market share in primary care by 2015.
- Rosuvastatin failed to make a significant effect on the English market.
- Retrospective study evaluated the changes in primary care use pattern of all statins in England between 1998 and 2015.
- Funding: None disclosed.
- Data derived from prescriptions dispensed rather than prescription written.